The FDA awarded Magstim, a Carmarthenshire, Wales firm, clearance to bring to market the company’s Magstim Rapid2 rTMS (repetitive Transcranial Magnetic Stimulation) Therapy System. The system is indicated to treat drug resistant major depressive disorder in an outpatient setting.
Discover The World's MOST COMPREHENSIVE Mental Health Assessment Platform
Efficiently assess your patients for 80+ possible conditions with a single dynamic, intuitive mental health assessment. As low as $12 per patient per year.
The Magstim Rapid2 has been available to researchers in fields such as cognitive neuroscience, neurophysiology, and rehabilitation. Now the magnetic stimulator will be available in the U.S. as a clinical product.
It’s intended to target the dorsolateral left pre-frontal cortex (DLPFC), a region of the brain that sees reduced blood flow in patients with serious depression. When magnetically stimulated, blood flow tends to increase, improving mood and reducing symptoms of the depression.
Here’s Robin Davies, the CEO of Magstim, talking about the Rapid2 rTMS system: